Public

Recro Pharma agreed to pay $1.4 million to settle a securities class action lawsuit accusing the Company of deceiving investors about material information.

The original complaint alleged that the Company and its Leaders misled investors through a series of public statements regarding Recro’s target opportunities that allegedly inflated Recro’s stock price, in particular, they misrepresented and/or omitted Key Opinion Leader concerns about the drug IV meloxicam.

Recro Pharma agreed to settle with investors to avoid further litigation.

Recro Pharma, Inc.

Accepting Late Claims

Other

Stocks

Long

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.